1. |
Woo D, Yu M. Circulating tumor cells as “liquid biopsies” to understand cancer metastasis. Transl Res, 2018, 201: 128-135.
|
2. |
Smerage JB, Budd GT, Doyle GV, et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol, 2013, 7(3): 680-692.
|
3. |
Noman MZ, Messai Y, Muret J, et al. Crosstalk between CTC, immune system and hypoxic tumor microenvironment. Cancer Microenviron, 2014, 7(3): 153-160.
|
4. |
Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev, 2010, 20(1): 96-99.
|
5. |
Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol, 2005, 23(8): 1623-1626.
|
6. |
Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res, 2018, 78(16): 4731-4744.
|
7. |
Erdbruegger U, Dhaygude A, Haubitz M, et al. Circulating endothelial cells: markers and mediators of vascular damage. Curr Stem Cell Res Ther, 2010, 5(4): 294-302.
|
8. |
Najjar F, Alammar M, Al-Massarani G, et al. Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer. Cancer Biomark, 2017, 20(3): 333-343.
|
9. |
Rahbari NN, Schölch S, Bork U, et al. Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget, 2017, 8(23): 37491-37501.
|
10. |
Bhakdi SC, Suriyaphol P, Thaicharoen P, et al. Accuracy of tumour-associated circulating endothelial cells as a screening biomarker for clinically significant prostate cancer. Cancers (Basel), 2019, 11(8): 1064.
|
11. |
Wee JT, Ha TC, Loong SL, et al. Is nasopharyngeal cancer really a “Cantonese cancer”?. Chin J Cancer, 2010, 29(5): 517-526.
|
12. |
Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma. Lancet, 2016, 387(10022): 1012-1024.
|
13. |
Zhang J, Shi H, Jiang T, et al. Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma. BMC Cancer, 2018, 18(1): 1133.
|
14. |
Hu B, Gong Y, Wang Y, et al. Comprehensive atlas of circulating rare cells detected by SE-iFISH and image scanning platform in patients with various diseases. Front Oncol, 2022, 12: 821454.
|
15. |
Giam M, Rancati G. Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div, 2015, 10: 3.
|
16. |
Dürrbaum M, Storchová Z. Effects of aneuploidy on gene expression: implications for cancer. FEBS J, 2016, 283(5): 791-802.
|
17. |
Li Y, Zhang X, Ge S, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget, 2014, 5(16): 6594-6602.
|
18. |
Yadav A, Kumar B, Yu JG, et al. Tumor-associated endothelial cells promote tumor metastasis by chaperoning circulating tumor cells and protecting them from anoikis. PLoS One, 2015, 10(10): e0141602.
|
19. |
Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res, 2020, 39(1): 204.
|
20. |
Altena R, Fehrmann RS, Boer H, et al. Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage. PLoS One, 2015, 10(1): e0115372.
|
21. |
Bayani J, Paderova J, Murphy J, et al. Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia, 2008, 10(10): 1057-1065.
|
22. |
Kyrodimos E, Chrysovergis A, Mastronikolis N, et al. Targeting EGFR in nasopharyngeal carcinoma. J BUON, 2021, 26(3): 759-761.
|